<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377650</url>
  </required_header>
  <id_info>
    <org_study_id>JagiellonianU</org_study_id>
    <nct_id>NCT00377650</nct_id>
  </id_info>
  <brief_title>Polish-Italian-Hungarian RAndomized ThrombEctomy Trial</brief_title>
  <official_title>Polish-Italian-Hungarian RAndomized ThrombEctomy Trial. PIHRATE Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <brief_summary>
    <textblock>
      Aim Primary percutaneous coronary intervention efficacy improvement by DIVER CE thrombectomy&#xD;
      system leading to thrombus reduction.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Multicenter, prospective, opened, randomized.&#xD;
&#xD;
      Primary endpoints:&#xD;
&#xD;
      ST resolution &gt;70% 60 minutes after PCI&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
      Thrombectomy system efficacy/passing trough lesion with thrombus reduction according do TIMI&#xD;
      thrombus scale ≥ 1 TIMI 3 flow after PCI MBG 3 CMR - infarct size, measurement of left&#xD;
      ventricular end-diastolic EDV and end-systolic volumes ESV and ejection fraction (EF) ECHO:&#xD;
      measurement of left ventricular end-diastolic EDV and end-systolic volumes ESV, ejection&#xD;
      fraction (EF) and wall motion score index (WMSI) Major cardiac events /cardiac death, reMI,&#xD;
      rePCI (TVR, TLR, non infarct involved vessel) or CABG/ 6 month follow up Rate of composite&#xD;
      angiographic adverse events including: distal embolisation, transient no-reflow or slow flow,&#xD;
      final TIMI &lt;3, need of bail out GpIIb/IIIa inhibitors or adenosine or nitroprosside, final&#xD;
      thrombus score &gt;1&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date>December 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ST resolution &gt;70% 60 minutes after PCI</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombectomy system efficacy/passing trough lesion with thrombus reduction according do TIMI thrombus scale ≥ 1</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI 3 flow after PCI</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MBG 3</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR - infarct size, measurement of left ventricular end-diastolic EDV and end-systolic volumes ESV and ejection fraction (EF)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO: measurement of left ventricular end-diastolic EDV and end-systolic volumes ESV, ejection fraction (EF) and wall motion score index (WMSI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiac events /cardiac death, reMI, rePCI (TVR, TLR, non infarct involved vessel) or CABG/ 6 month follow up</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of composite angiographic adverse events including: distal embolisation, transient no-reflow or slow flow, final TIMI &lt;3, need of bail out GpIIb/IIIa inhibitors or adenosine or nitroprosside, final thrombus score &gt;1</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous thrombectomy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ST elevation acute myocardial infarction within 6 hours since pain onset, with 2 mm ST&#xD;
             segment elevation in two lead&#xD;
&#xD;
          -  Minimum 3 mm ST segment elevation in one leads&#xD;
&#xD;
          -  Vessel reference diameter &gt; 2.5 mm&#xD;
&#xD;
          -  When vessel reference diameter ≥ 4,0 mm than additional distal protection device&#xD;
             (filter) is needed during stent implantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to PCI (contrast allergy, no possibility to stent implantation) ASA,&#xD;
             thienopirydins or GP IIb/IIIa inhibitors&#xD;
&#xD;
          -  Active bleeding or coagutopathy&#xD;
&#xD;
          -  Prior CABG or PCI&#xD;
&#xD;
          -  Known ejection fraction EF &lt;35%&#xD;
&#xD;
          -  Cardiogenic shock /SBP &lt; 90 mmHg, IABP and/or catheloamins usage/&#xD;
&#xD;
          -  LBBB, pacemaker rhythm&#xD;
&#xD;
          -  Severe calcifications&#xD;
&#xD;
          -  Previous Myocardial infarction&#xD;
&#xD;
          -  Stroke history&#xD;
&#xD;
          -  Patient directly after reanimation&#xD;
&#xD;
          -  Known thrombocytopenia- platelets &lt; 100 000&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Cancer disease&#xD;
&#xD;
          -  No future patient cooperation expected&#xD;
&#xD;
          -  Patient's taking part in the other clinical trials&#xD;
&#xD;
          -  Fibrynolisis directly administered before PCI&#xD;
&#xD;
          -  Renal insufficiency (creatynine &gt; 220 µmol/ml), hemodialysis&#xD;
&#xD;
          -  Contraindications to PCI (contrast allergy, no possibility to stent implantation) ASA,&#xD;
             thienopirydins or GP IIb/IIIa inhibitors&#xD;
&#xD;
          -  Active bleeding or coagutopathy&#xD;
&#xD;
          -  Prior CABG or PCI&#xD;
&#xD;
          -  Known ejection fraction EF &lt;35%&#xD;
&#xD;
          -  Cardiogenic shock /SBP &lt; 90 mmHg, IABP and/or catheloamins usage/&#xD;
&#xD;
          -  LBBB, pacemaker rhythm&#xD;
&#xD;
          -  Severe calcifications&#xD;
&#xD;
          -  Previous Myocardial infarction&#xD;
&#xD;
          -  Stroke history&#xD;
&#xD;
          -  Patient directly after reanimation&#xD;
&#xD;
          -  Known thrombocytopenia- platelets &lt; 100 000&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Cancer disease&#xD;
&#xD;
          -  No future patient cooperation expected&#xD;
&#xD;
          -  Patient's taking part in the other clinical trials&#xD;
&#xD;
          -  Fibrynolisis directly administered before PCI&#xD;
&#xD;
          -  Renal insufficiency (creatynine &gt; 220 µmol/ml), hemodialysis&#xD;
&#xD;
          -  Liver insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariusz Dudek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jagiellonian University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dariusz Dudek, MD</last_name>
    <phone>124247181</phone>
    <phone_ext>+48</phone_ext>
    <email>mcdudek@cyf-kr.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute, Medical School of University Pecs</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Horvath, MD</last_name>
      <email>ivan.g.horvath@aok.pte.hu</email>
    </contact>
    <investigator>
      <last_name>Ivan Horvath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology Department Hospital Villascassi</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Rubartelli, MD</last_name>
      <email>paolo.rubartelli@villascassi.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Rubartelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology, Catholic University</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Burzotta, MD</last_name>
      <email>f.burzotta@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Burzotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Górnośląskie Centrum Medyczne</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Ochala, Md</last_name>
      <email>aochala@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Andrzej Ochała, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaklad Hemodynamiki i Angiokardiohrafii IK CMUJ</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waldemar A Mielecki, MD</last_name>
      <phone>124247181</phone>
      <phone_ext>+48</phone_ext>
      <email>wmielecki@su.krakow.pl</email>
    </contact>
    <investigator>
      <last_name>Dariusz Dudek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Waldemar A Mielecki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oddział Kardiologii Inwazyjnej, Elektroterapii i Angiologii NZOZ</name>
      <address>
        <city>Nowy Sacz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Korpak-Wysocka, MD</last_name>
      <phone>184407487</phone>
      <phone_ext>+48</phone_ext>
    </contact>
    <investigator>
      <last_name>Renata Korpak-Wysocka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dawid Giszterowicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki w Przemyślu</name>
      <address>
        <city>Przemyśl</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Wiśniewski, MD</last_name>
      <phone>166775000</phone>
      <phone_ext>+48</phone_ext>
    </contact>
    <investigator>
      <last_name>Andrzej Wiśniewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Kardiologii im.Prymasa Tysiaclecia Sefana Kardynala Wyszynskiego</name>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Witkowski, MD</last_name>
      <email>witkowski@hbz.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Witkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slaskie Centrum Chorob Serca</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariusz Gasior, MD</last_name>
      <email>m.gasior@sccs.pl</email>
    </contact>
    <investigator>
      <last_name>Mariusz Gasior, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>September 14, 2006</study_first_submitted>
  <study_first_submitted_qc>September 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2006</study_first_posted>
  <last_update_submitted>January 16, 2007</last_update_submitted>
  <last_update_submitted_qc>January 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

